|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RASSF1A is a tumor suppressor gene, and its hypermethylation has been observed in cancers.
|
31754973 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>RASSF1A, E-Cadherin</i> and <i>RUNX3</i> are tumour suppressor genes that may be inactivated by hypermethylation in many tumours including hepatocellular carcinoma (HCC).
|
31790342 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RASSF1A (Ras association domain family 1 isoform A) is a tumor suppressor and frequently inactivated by promoter hypermethylation in hepatocellular carcinoma (HCC).
|
30315205 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, methylated RASSF1A and p14/ARF were associated with the grade of CRC but not associated with the age of patients, family history, or tumor location.
|
30989570 |
2019 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
RASSF1A methylation measured in tumor or blood was predictive for response to neoadjuvant chemotherapy.
|
30190521 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although encoded by the same gene, RASSF1A and RASSF1C are two opposites in carcinogenesis; one is a tumor suppressor that is silenced in a plethora of cancers, while the other is an oncogene that remains unaffected.
|
31735284 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
New type of interaction between the SARAH domain of the tumour suppressor RASSF1A and its mitotic kinase Aurora A.
|
30944388 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The Ras association domain family isoform 1A (RASSF1A) is a cellular tumor suppressor, which regulates a broad range of cellular functions, including apoptosis, cell-cycle arrest, mitotic arrest, and migration.
|
30615685 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we show that adverse prognosis associated with epigenetic silencing of the tumour suppressor RASSF1A is due to increased deposition of extracellular matrix (ECM), tumour stiffness and metastatic dissemination in vitro and in vivo.
|
31268606 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RASSF1A encodes a tumor suppressor that inhibits the RAS→RAF→MEK→ERK pathway and is one of the most frequently inactivated genes in human cancers.
|
31435022 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings suggest that tumor suppression proteins RASSF1A and LATS1/2 may be involved in the pathogenesis of human IBD and imply a potential cooperation of RASSF1A, and HIPPO signaling pathways in human bowel inflammation.
|
30604274 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study is to determine the efficacy of combined DNA methylation analysis of a global DNA methylation marker - LINE-1 and a tumor suppressor gene highly associated with the malignancy of HCC- RASSF1A in serum as a novel prognostic marker for diagnosis of early recurrence after curative resection.LINE-1 was hypomethylated in 66.7% (70/105) and RASSF1A promoter was hypermethylated in 73.3% (77/105) of HCC serum DNA samples by methylation specific PCR, but in none of the healthy controls: LINE-1 hypometylation (0/50) and RASSF1A hypermethylation (0/50).
|
28592132 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RASSF1A (Ras association domain family 1 isoform A) is a tumour suppressor gene frequently silenced by promoter hypermethylation in all major solid cancers.
|
31414556 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial.
|
31766357 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we leveraged several approaches, including global and regional ischemia/reperfusion (I/R), genetically modified mice, and primary cell culture, to investigate the cell type-specific function of the tumor suppressor Ras association domain family member 1 isoform A (RASSF1A) in cardiac inflammation.
|
31311858 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This could facilitate a deeper understanding of tumor development and provide us with new strategies in cancer treatment by targeting the RASSF1A pathway.
|
31804463 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Methylation of RASSF1A gene was associated with age, tumor size, vascular invasion and α fetoprotein (AFP), while SOCS-1 gene methylation was significantly associated with tumor size and AFP.
|
30689554 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ras association domain family 1A (RASSF1A) is a scaffold protein that acts as a tumour suppressor.
|
31086178 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
An inverse relationship in expression of oncogenic FoxM1 and tumor suppressor RASSF1A was observed in various stages of CRC.
|
30744076 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RASSF1A, a tumor suppressor gene, is frequently inactivated in lung cancer leading to a YAP-dependent epithelial-mesenchymal transition (EMT).
|
30979377 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
<i>DLEC1</i> methylation was frequently detected in ESCC tumors and correlated with lymph node metastasis, tumor recurrence and progression, with <i>DLEC1</i> as the most frequently methylated among the established 3p22.2 tumor suppressors (<i>RASSF1A, PLCD1</i> and <i>ZMYND10/BLU</i>).
|
29290793 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The tumor suppressors PTEN and RASSF1A were de-repressed following DNMT3B inhibition in TERT-depleted HCC cells.
|
30017965 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results may have considerable ramifications for future targeted therapy against RAS<sup>+</sup>/RASSF1A<sup>-</sup> tumors.<b>Significance:</b> A transgenic mouse model shows that suppression of RASSF1A dramatically enhances Ras-driven tumorigenesis and alters Ras signaling pathway activity.<b>Graphical Abstract:</b> http://cancerres.aacrjournals.org/content/canres/78/10/2614/F1.large.jpg <i></i>.
|
29735543 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we show that the tumour suppressor RASSF1A is a key player driving the early specification of cell fate.
|
29382819 |
2018 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
RASSF1A promoter methylation was associated with tumor grade (grade 3-4 vs 1-2: OR 2.31, 95% CI 1.12-4.77, P = 0.023), lymph node metastasis (yes vs no: OR 2.97, 95% CI 1.60-5.52, P = 0.001), tumor histology (squamous cell carcinoma vs adenocarcinoma: OR 0.49, 95% CI 0.22-1.08, P = 0.076), and HPV infection (positive vs negative: OR 0.45, 95% CI 0.28-0.73, P = 0.001).
|
29288321 |
2018 |